A 58-year-old man from Delhi presents with progressive dyspnea on exertion for 3 months, orthopnea, and paroxysmal nocturnal dyspnea. He has a history of hypertension (on amlodipine 5 mg daily) and type 2 diabetes. On examination, BP 148/92 mmHg, HR 98/min, JVP elevated at 8 cm, bilateral basal crackles, and a displaced apex beat at 6th intercostal space. Echocardiography shows LVEF 35%, global hypokinesis, and no significant valvular disease. Serum creatinine 1.4 mg/dL, potassium 4.2 mEq/L. What is the most appropriate next step in management?

Explanation

## Diagnosis: Systolic Heart Failure (HFrEF) This patient has heart failure with reduced ejection fraction (HFrEF) based on LVEF 35%, clinical signs of pulmonary and systemic congestion, and absence of valvular disease. ## Pathophysiology **Key Point:** HFrEF management follows a stepwise, evidence-based approach targeting neurohormonal antagonism and symptom relief. 1. **ACE inhibitor (or ARB)** — reduces afterload, prevents remodeling, improves survival 2. **Beta-blocker** — reduces sympathetic tone, slows progression, improves ejection fraction 3. **Loop diuretic** — relieves congestion (orthopnea, PND, crackles) 4. **Aldosterone antagonist** — added later if persistent symptoms or reduced K^+^ ## Rationale for Option 2 (Correct) | Component | Rationale | |-----------|----------| | **Lisinopril 2.5 mg** | Low starting dose in renal impairment (Cr 1.4); titrate up as tolerated | | **Carvedilol 3.125 mg** | Evidence-based beta-blocker; start low, titrate slowly | | **Furosemide 40 mg** | Addresses congestion; adjust based on clinical response | | **Sodium restriction** | Reduces fluid retention; cornerstone of HF counseling | **High-Yield:** The PARADIGM-HF, CIBIS, COPERNICUS, and MERIT-HF trials established that ACE-I + beta-blocker combination reduces mortality in HFrEF. **Clinical Pearl:** In a patient with mild renal impairment (Cr 1.4) and normal K^+^ (4.2), start ACE-I at low dose and titrate cautiously. Aldosterone antagonists are added only if EF remains ≤35% after 4–6 weeks of ACE-I + beta-blocker, or if K^+^ is ≤5.0 mEq/L. ## Why Not the Other Options? **Option 0 (Lisinopril 5 mg + furosemide alone):** - Omits beta-blocker, which is a cornerstone of HFrEF therapy - Monotherapy with ACE-I is suboptimal; combination therapy reduces mortality **Option 1 (Metoprolol + increased amlodipine + transplant referral):** - Premature transplant referral; patient has not yet received guideline-directed medical therapy (GDMT) - Amlodipine is a dihydropyridine (reflex tachycardia); not first-line for HFrEF - Metoprolol is acceptable but carvedilol/bisoprolol have superior mortality data in HFrEF **Option 3 (Spironolactone + digoxin first-line):** - Spironolactone is added later, not as initial therapy; risk of hyperkalemia in renal impairment - Digoxin has no mortality benefit; used only for rate control in AF or symptomatic relief - Omits ACE-I and beta-blocker, the foundational agents ## Management Algorithm ```mermaid flowchart TD A[HFrEF diagnosed<br/>LVEF ≤40%]:::outcome --> B[Initiate ACE-I/ARB<br/>+ Beta-blocker<br/>+ Loop diuretic]:::action B --> C{Symptoms<br/>improved?}:::decision C -->|Yes| D[Uptitrate ACE-I<br/>and beta-blocker<br/>to target doses]:::action C -->|No| E[Add aldosterone<br/>antagonist or<br/>ARNI]:::action D --> F{EF improved<br/>or stable?}:::decision E --> F F -->|Yes| G[Continue GDMT<br/>+ ICD if EF ≤35%<br/>after 40 days]:::action F -->|No| H[Consider advanced<br/>therapies:<br/>CRT, VAD, transplant]:::urgent ``` **Key Point:** GDMT (guideline-directed medical therapy) is the foundation. ACE-I + beta-blocker + diuretic is the minimum; aldosterone antagonists, ARNI, and SGLT2 inhibitors are added sequentially based on response and tolerance.